"Farmakoterapeutick\u00E9 informace" . "RIV/00023884:_____/10:#0004238!RIV12-MZ0-00023884" . . "Angiotensin-converting enzyme inhibitors, cardiovascular disease"@en . . . "1211-0647" . "[058FED1BEBEC]" . . "N" . . . . "10" . . . . . "Postaven\u00ED inhibitor\u016F angiotenzin-konvertuj\u00EDc\u00EDho enzymu v terapii kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED"@cs . "Angiotensin-converting enzyme inhibitors (ACEIs) have broad indication: ACEIs are widely used in the therapy of arterial hypertension, cardiac dysfunction post myocardial infarction and in the management of chronic heart failure. Research showed other possibilities of ACEIs use. Results of large clinical trials support importance of ACEIs in the cardiovascular event prevention in high risk subjects, secondary prevention of ischemic stroke, and vascular complication in patients with diabetes mellitus. Current guidelines recommend to start medical therapy of moderate to severe arterial hypertension with low dose of drug combination. ACEIs are reasoned choice for drug combination thanks to their cardioprotective effect. ACEIs are now used for the medical therapy of arterial hypertension in the combination with diuretics and calcium channel blockers"@en . "2010" . . "Postaven\u00ED inhibitor\u016F angiotenzin-konvertuj\u00EDc\u00EDho enzymu v terapii kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED" . "Inhibitory angiotenzin-konvertuj\u00EDc\u00EDho enzymu (ACEI) jsou nejd\u00E9le pou\u017E\u00EDvanou l\u00E9kovou skupinou, kter\u00E1 zasahuje do syst\u00E9mu renin-angiotenzin-aldosteron. ACEI maj\u00ED p\u0159edn\u00ED m\u00EDsto v terapii arteri\u00E1ln\u00ED hypertenze, v l\u00E9\u010Db\u011B nemocn\u00FDch se srde\u010Dn\u00ED dysfunkc\u00ED po infarktu myokardu a v terapii chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED. Pokra\u010Duj\u00EDc\u00ED z\u00E1kladn\u00ED a klinick\u00FD v\u00FDzkum ukazuje \u0161ir\u0161\u00ED mo\u017Enosti pou\u017Eit\u00ED t\u011Bchto l\u00E9k\u016F. Poznatky z randomizovan\u00FDch klinick\u00FDch studi\u00ED podporuj\u00ED v\u00FDznam ACEI v prevenci kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod u pacient\u016F s vysok\u00FDm rizikem, v sekund\u00E1rn\u00ED prevenci c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod, v prevenci vaskul\u00E1rn\u00EDch komplikac\u00ED diabetes mellitus. V l\u00E9\u010Db\u011B arteri\u00E1ln\u00ED hypertenze jsou pou\u017E\u00EDv\u00E1ny jak v monoterapii, tak ve fixn\u00ED kombinaci s diuretiky a s blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F."@cs . "Inhibitory angiotenzin-konvertuj\u00EDc\u00EDho enzymu (ACEI) jsou nejd\u00E9le pou\u017E\u00EDvanou l\u00E9kovou skupinou, kter\u00E1 zasahuje do syst\u00E9mu renin-angiotenzin-aldosteron. ACEI maj\u00ED p\u0159edn\u00ED m\u00EDsto v terapii arteri\u00E1ln\u00ED hypertenze, v l\u00E9\u010Db\u011B nemocn\u00FDch se srde\u010Dn\u00ED dysfunkc\u00ED po infarktu myokardu a v terapii chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED. Pokra\u010Duj\u00EDc\u00ED z\u00E1kladn\u00ED a klinick\u00FD v\u00FDzkum ukazuje \u0161ir\u0161\u00ED mo\u017Enosti pou\u017Eit\u00ED t\u011Bchto l\u00E9k\u016F. Poznatky z randomizovan\u00FDch klinick\u00FDch studi\u00ED podporuj\u00ED v\u00FDznam ACEI v prevenci kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod u pacient\u016F s vysok\u00FDm rizikem, v sekund\u00E1rn\u00ED prevenci c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod, v prevenci vaskul\u00E1rn\u00EDch komplikac\u00ED diabetes mellitus. V l\u00E9\u010Db\u011B arteri\u00E1ln\u00ED hypertenze jsou pou\u017E\u00EDv\u00E1ny jak v monoterapii, tak ve fixn\u00ED kombinaci s diuretiky a s blok\u00E1tory kalciov\u00FDch kan\u00E1l\u016F." . "Postaven\u00ED inhibitor\u016F angiotenzin-konvertuj\u00EDc\u00EDho enzymu v terapii kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED"@cs . "Role of angiotensin-converting enzyme inhibitors in the treatment of cardiovascular diseases"@en . "1"^^ . . "CZ - \u010Cesk\u00E1 republika" . "Role of angiotensin-converting enzyme inhibitors in the treatment of cardiovascular diseases"@en . "4"^^ . "1"^^ . "RIV/00023884:_____/10:#0004238" . "Postaven\u00ED inhibitor\u016F angiotenzin-konvertuj\u00EDc\u00EDho enzymu v terapii kardiovaskul\u00E1rn\u00EDch onemocn\u011Bn\u00ED" . "M\u00E1lek, Filip" . "280289" .